Palvella Therapeutics, Inc.
PVLA Nasdaq
SEC CIK 1583648
Follow Palvella Therapeutics
Weekly email: filings, results
Net income
−$24.6M
−117.2% vs same quarter last year
EPS, diluted
−$1.70
−65% vs same quarter last year
Operating cash flow
−$14.4M
−83.1% vs same quarter last year
Operating income
−$22.7M
−123.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | −$41.7M |
| FY24 | - | −$17.4M |
| FY23 | $42.8M | $18.7M |
| FY22 | $25.9M | −$33.3M |
| FY21 | $31.4M | −$45.7M |
| FY20 | $29.3M | −$37.2M |
| FY19 | $43.6M | −$25.5M |
| FY18 | $27.2M | −$26.8M |
| FY17 | $25.3M | −$17.6M |
| FY16 | $5.8M | −$22.8M |
| FY15 | $2.9M | −$14.1M |
| FY14 | $5.4M | −$9.8M |
| FY13 | $12.4M | $66.2K |
| FY12 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | - | - |
| FY24 | - | - |
| FY23 | −27.7% | 43.7% |
| FY22 | −167.8% | −128.5% |
| FY21 | −165% | −145.6% |
| FY20 | −115.7% | −127% |
| FY19 | −62.2% | −58.4% |
| FY18 | −113.1% | −98.2% |
| FY17 | −57.7% | −69.8% |
| FY16 | −390.3% | −391% |
| FY15 | −466.6% | −479.5% |
| FY14 | −134.2% | −183.6% |
| FY13 | 4.5% | 0.5% |
| FY12 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | −$13.9M |
| FY22 | −$61M |
| FY21 | −$8.6M |
| FY20 | −$48.6M |
| FY19 | −$54.9M |
| FY18 | −$2.8M |
| FY17 | $47.8M |
| FY16 | −$14.9M |
| FY15 | −$13.3M |
| FY14 | −$282.5K |
| FY13 | −$3.1M |
| FY12 | - |
- Palvella Therapeutics
- Healthcare median
Show the numbers
| Year | Palvella Therapeutics | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | - | −47% |
| FY23 | 43.7% | −58% |
| FY22 | −128.5% | −80.4% |
| FY21 | −145.6% | −71.9% |
| FY20 | −127% | −62.2% |
| FY19 | −58.4% | −46.3% |
| FY18 | −98.2% | −49.6% |
| FY17 | −69.8% | −45.9% |
| FY16 | −391% | −36% |
| FY15 | −479.5% | −38.4% |
| FY14 | −183.6% | −35.5% |
| FY13 | 0.5% | −37.1% |
| FY12 | - | −29.1% |